Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou, 115 27 Athens, Greece.
Expert Rev Proteomics. 2009 Dec;6(6):661-74. doi: 10.1586/epr.09.85.
The evidence on the mechanisms underlying schizophrenia seems to support a series of divergent possibilities that may play a contributory role in the disease pathogenesis. Hypotheses regarding disease mechanisms range from structural and neurodevelopmental abnormalities to neurotransmitter deficits and genetic predisposition. Nevertheless, little progress has been made in the field of schizophrenia with respect to the key pathophysiological processes, and this is a fundamental barrier to identifying or predicting the therapeutic value of novel drug targets. All multi-omics approaches, including proteomics, would be perfectly suited to such a complex disease as a means of tackling the widening chasm between the aforementioned hypotheses. Proteomic studies have been performed in a variety of tissues and biological fluids, from post-mortem CNS tissue to cerebrospinal fluid and blood, and in recently generated mutant animal models with schizophrenia-like phenotypes. In this review, we present an overview of several proteomic studies in the field of schizophrenia research and discuss how proteomics could assist with identifying schizophrenia markers more efficiently, covering both clinical and basic research.
精神分裂症发病机制相关的证据似乎支持一系列不同的可能性，这些可能性可能在疾病发病机制中起作用。关于疾病机制的假说范围从结构和神经发育异常到神经递质缺乏和遗传易感性。然而，在精神分裂症领域，关键的病理生理过程方面几乎没有取得进展，这是确定或预测新型药物靶点治疗价值的一个基本障碍。所有多组学方法，包括蛋白质组学，都非常适合用于处理上述假说之间日益扩大的差距，这是一种复杂的疾病。蛋白质组学研究已经在多种组织和生物液中进行，从死后中枢神经系统组织到脑脊液和血液，以及最近生成的具有精神分裂症样表型的突变动物模型中进行。在这篇综述中，我们介绍了精神分裂症研究领域的几项蛋白质组学研究概述，并讨论了蛋白质组学如何更有效地帮助识别精神分裂症标志物，涵盖了临床和基础研究。
